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Abstract
Background: Hereditary hemochromatosis (HH) is a common autosomal recessive disorder amongst persons of
northern European heritage. If untreated, iron accumulates in parenchymal tissues causing morbidity and mortality.
As diagnosis often follows irreversible organ damage, screening programs have been suggested to increase early
diagnosis. A lack of economic evidence has been cited as a barrier to establishing such a program. Previous
analyses used poorly estimated utility values. This study sought to measure utilities directly from people with HH in
Australia.
Methods: Volunteers with HH were recruited to complete a web-based survey. Utility was assessed using the
Assessment of Quality of Life 4D (AQOL-4D) instrument. Severity of HH was graded into four categories.
Multivariable regression analysis was performed to identify parameters associated with HSUV.
Results: Between November 2013 and November 2014, 221 people completed the survey. Increasing severity of
HH was negatively associated with utility. Mean (standard deviation) utilities were 0.76 (0.21), 0.81 (0.18), 0.60 (0.27),
and 0.50 (0.27) for categories 1–4 HH respectively. Lower mean utility was found for symptomatic participants
(categories 3 and 4) compared with asymptomatic participants (0.583 v. 0.796). Self-reported HH-related symptoms
were negatively associated with HSUV (r = −0.685).
Conclusions: Symptomatic stages of HH and presence of multiple self-reported symptoms were associated with
decreasing utility. Previous economic analyses have used higher utilities which likely resulted in underestimates of
the cost effectiveness of HH interventions. The utilities reported in this paper are the most robust available, and will
contribute to improving the validity of future economic models for HH.
Background
Hereditary hemochromatosis (HH) is a common auto-
somal recessive disorder in populations of northern
European heritage [1, 2]. It is characterised by increased
iron absorption caused by a defect in the HFE gene. Sev-
eral mutations have been identified: C282Y, H63D and
S56C [3–5]. C282Y homozygosity accounts for 80 to
90 % of people diagnosed with iron-overload, with the
other mutations uncommonly associated with iron over-
load [6, 7]. It has been hypothesised that HH is most
prevalent in northern European populations due to a
mutation occurring in Central Europe, hence the de-
scription ‘Celtic mutation” [8]. Prevalence of C282Y
homozygosity has been reported to be between 1 in 150
to 200 persons of Northern European ancestry. Amongst
populations of different heritage, prevalence is much
lower: 1 in 300 Hispanics; 1 in 1,000 Native Americans;
1 in 1,000, 000 Asians [9–13]. Whilst prevalence of other
genotypes is more common (1 in 50 C282Y/H63D com-
pound heterozygotes), the burden of disease associated
with these mutations is low [4, 14].
In a proportion of C282Y homozygotes, elevated hep-
cidin production increases the absorption of dietary iron,
which is stored in the parenchymal tissues of the heart,
liver and pancreas. If left untreated, iron overload can be
a cause of morbidity and mortality, including multiple
arthropathies, type 2 diabetes, liver disease and heart
disease [15–17]. HH and iron overload is commonly di-
agnosed by conducting iron studies (transferrin satur-
ation and serum ferritin) with confirmatory genotyping.
Treatment consists of regular therapeutic venesection.
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Rates of clinical penetrance (i.e. expression of disease)
reported in the literature vary, in part due to different
definitions. Some authors have defined penetrance as ir-
reversible organ damage, such as cirrhosis or hepatocel-
lular carcinoma, whilst other have included a spectrum
of health states, from elevated iron stores and serum
iron through to irreversible organ damage. Recent stud-
ies have reported rates of cirrhosis of the liver amongst
C282Y homozygotes to be between 2 and 6 % [10, 18,
19]. When penetrance is defined as elevated iron stores
and serum iron through to irreversible organ damage,
rates of 28.4 % for male and 1.2 % for female C282Y ho-
mozygotes have been recently reported [10].
Whilst diagnosis and prevention of iron overload in
genetically susceptible patients is relatively straightfor-
ward, the non-specific nature of early symptomatology,
in that this can be experienced by people with clinically
normal iron levels, contributes to some patients being
diagnosed only after irreversible organ damage has oc-
curred [20–23]. Effective treatment is readily available,
therefore early diagnosis and timely treatment leads to
substantial improvements in patient outcomes. Popula-
tion screening strategies have been proposed as an ap-
proach to increase early identification of people with
HH, thereby reducing the potential burden of disease as-
sociated with iron overload [24–28].
Whilst HH is a condition that fulfils several of the criteria
set out by the World Health Organisation for population
screening programs [29], a lack of robust health economic
data has been cited as a hurdle to implementing such a
program [24, 25, 30, 31]. Considerable limitations have
been identified in the economic evaluations of HH screen-
ing programs that have been published to date [32, 33].
Cost effectiveness analyses and cost utility analyses
give rise to a ratio of the difference in costs and effect-
iveness between two or more health interventions. The
cost of an intervention is measured in monetary units
and effectiveness may be measured unidimensionally for
cost effectiveness analyses (e.g. life years gained) or by
means of a multidimensional instrument (such as the
EQ-5D, SF-6, AQOL-4D) for cost utility analyses. Im-
portantly, multi-attribute utility instruments allow for
calculation of an individual’s utility (HSUV): a measure
of the strength of preference for a particular health state.
Utilities are measured on a scale of zero to one, with
one representing full health, and zero, death. Some in-
struments such as the AQOL-4D and the EQ-5D allow
for negative values, as certain states may be considered
worse than death [36, 37]. When a utility is combined with
life years gained (LYG), the outcome reflects both morbid-
ity and mortality: quality adjusted life years (QALYs). A
cost per QALY can then be reported, the preferred unit of
measurement of many decision makers, such as the UK’s
National Institute for Health and Care Excellence (NICE)
[34] and the Australian Pharmaceutical Benefits Advisory
Committee (PBAC) [35].
To date, just four cost utility studies of HH screening
programs have been published [33]. The studies did not
report the sources of the utilities used, and the estimates
employed for conditions such as healthy state, heart
disease and cirrhosis of the liver were markedly higher
than reported for comparable populations [33]. Such use
of elevated utility values is likely to result in underesti-
mates of the potential gains associated with screening
programs, which in turn may impact on policy decisions
regarding provision of HH screening programs.
The purpose of this study was to assess the utilities for a
sample of people with HH with different stages of disease
severity using a multi-attribute utility instrument.
Methods
A web-based cross-sectional study using convenience
sampling was conducted across Australia. Multiple re-
cruitment strategies were used: the national support
group, Hemochromatosis Australia (HA), sent emails to
all members on behalf of the researchers informing them
of the project and the web address; the link to the survey
was placed on HA’s website; flyers outlining the study
were sent to large Australian metropolitan hepatology,
haematology and gastroenterology clinics, along with
general practitioners sourced from HA’s referral network;
advertisements were placed on social media sites; and
newspaper articles about the condition and the study were
published. In addition, case finding was conducted in all
Tasmanian public hospitals. All patients admitted between
July 2009 and June 2014 with a diagnosis of HH, as identi-
fied in the International Statistical Classification of Dis-
eases and Related Health Problems, Tenth Revision,
Australian Modification (ICD-10-AM) by code E831:
Disorders of Iron Metabolism, were sent letters by the
research group, informing them of the study and inviting
them to participate. Only names and postal details were
supplied to the researchers. Eligibility criteria included a
diagnosis of haemochromatosis, residing in Australia, aged
18 or older and provision of written informed consent.
Ethical approval for the study was granted by the Tasman-
ian Health and Medical Research Ethics Committee
(H0013564).
Measurements
HSUV
Utility was measured using the Assessment of Quality of
Life 4D instrument (AQOL-4D) [38]. The AQOL-4D is a
12 item questionnaire that provides a global health state
utility value. It consists of four separate dimensions: inde-
pendent living, relationships, mental health and senses.
The HSUV is scored on a scale from −0.04 to 1.00. A
de Graaff et al. Health and Quality of Life Outcomes  (2016) 14:31 Page 2 of 9
score of one represents optimal health, a score of zero
represents a state equivalent to death, and scores less than
zero represent states worse than death [38]. This instru-
ment was chosen as it is sensitive to a broad range of
conditions and health states [39], Australian population
normative data were available for comparison [40], and
due to cost and software limitations associated with the
use of other instruments. AQOL HSUV were calculated
using syntax supplied by the AQOL Group [41].
HH-related health states
Stages of HH were categorised using the framework
published by the European Association for the Study of
the Liver (EASL) [16]. The expert panel identified a lack
of generalizability of much of the research into HH, in
part due to researchers and clinicians using different defi-
nitions or descriptions of HH, i.e. genetic mutation only,
through to organ damage. To address this, EASL recom-
mended using uniform categorisation of the different
stages of HH. These categories are described in Table 1.
Participants were provided with this matrix, and asked to
categorise their condition. These self-categorisations were
verified by cross-checking responses with regard to recent
experience of HH comorbidities. Just one discrepancy was
identified: recoding for the more conservative categorisa-
tion was carried out and comorbidities were assumed to
be unrelated to HH.
Lists of commonly reported HH-related comorbidities
and symptoms were compiled following a review of the lit-
erature. Comorbidities included osteoarthritis, liver diseases
(fibrosis, cirrhosis, hepatocellular carcinoma), heart failure,
cardiomyopathy, Type 2 diabetes and porphyria cutanea
tarda. Participants were asked if they had been diagnosed
with each condition and if it was a) related to HH, b) not
related to HH, or c) unsure if related to HH. Only condi-
tions for which the participant stated were related to HH
were included in analyses. In order to capture data on pos-
sible undiagnosed comorbidities and general symptoms of
iron overload, participants were asked if they had experi-
enced a range of symptoms in the last three months that
they considered were related to HH. Symptoms associated
with HH included the general effects of iron overload, such
as fatigue, along with symptoms of liver disease, heart
failure, cardiomyopathy, arthritis, porphyria cutanea tarda
and changes to the reproductive system (e.g. decreased
libido).
Statistical analyses
Statistical analyses were performed using SPSS version
20.0.0. Chi square and ANOVA were used for descriptive
statistics. Differences between HH utilities and data from
other population groups were analysed using T-tests and
Kruskal Wallis one way analysis of variance. Linear re-
gression was carried out to identify the association be-
tween co-morbidity count and utility. A Pearson
correlation coefficient was calculated for utility values
and severity of HH.
Results
Demographics
Two hundred and seventy participants self-completed a
web-based survey between November 2013 and November
2014 as part of a national cost of illness study for HH. Two
hundred and twenty one participants completed the
AQOL-4D. The demographic characteristics of participants
are presented in Table 2. The only notable difference
between participants who completed the AQOL-4D and
those who did not was that the former were more likely to
be employed full time (X2 = 4.254, p = 0.026) (Table 2).
Due to the sampling techniques, it is not possible to
quantify the number of people who viewed information
regarding the study, thus calculating a response rate.
However, for the case finding at all Tasmanian public
hospitals, a response rate of 20 % was observed (37 par-
ticipants from 189 letters).
AQOL-4D HSUV
The mean utility for all participants using the AQol-4D
was 0.66 (±0.26), with a range of −0.04 to 1.00 (95 % CI
0.63–0.70) (Table 3). This was lower than the Australian
population norm estimated using the AQoL-4D of 0.81
(n = 8839, SD = 0.22, 95 % CI 0.81–0.82) [40].
Univariate analyses were carried out to examine utilities
for age and sex (Table 3). This showed similar values for
males (0.69) and females (0.64) (p = 0.163). Utilities were
also examined by age deciles and sex. Whilst slightly
higher mean utility values were reported for males for
most age deciles, none of these differences were found to
be statistically significant. Overall, utility was highest for
participants aged between 30 and 39 (0.72), and lowest for
those aged 70–79 (0.61).
Reporting of utility by stages of severity of HH (Table 1)
can help mitigate any bias due to the sampling approach.
A trend of decreasing HSUV was identified with stages
three and four (Table 4). A Pearson correlation coefficient
was calculated to assess the relationship between mean
utility and stages of HH: a moderate negative correlation
was found (r = −0.366; p < 0.001). Whilst lower mean
Table 1 Categories of HH [11]
Category
1
Genetic mutation only (C282Y homozygotes, H63D
heterozygotes and compound heterozygotes)
Category
2
Genetic mutation and elevated iron studies, either transferrin
saturation or serum iron
Category
3
Genetic mutation, elevated iron levels and early symptoms,
including arthritis, fatigue
Category
4
Genetic mutation, elevated iron levels and organ damage
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HSUV were reported for female participants for each
category, these differences were not significant.
To investigate the impact of symptomatic HH on utility,
the four categories of HH were combined into asymptom-
atic (categories 1 and 2), and symptomatic (categories 3
and 4) participants. Utility was significantly lower for the
symptomatic group for males (0.85 v. 0.59: H = 25.36,
p < 0.001), females (0.75 v. 0.58: H = 14.90, p < 0.001)
and overall (0.80 v. 0.58: H = 38.79, p < 0.001) (Table 5).
In keeping with these findings, evaluation of the impact
of HH related comorbidities on utility found all comorbidi-
ties were related to lower mean utility than reported for
participants reporting no comorbidities (0.76) and the
entire HH cohort (0.66) (Table 6). Using the sample mean
utility value as the reference case (0.66), participants self-
reporting arthritis related to HH had a lower mean utility
(0.52: F(1,198) = 10.854, p = 0.001). Whilst lower mean
utility values were reported for fibrosis, cirrhosis, heart
Table 2 Demographic characteristics of the sample
AQol-4D completers AQoL-4D non-completers p value
n = 221 n = 47
Age, mean ± SD 52.7 ± 14.2 53.6 ± 13.2 0.694
Sex (male) 41.6 % 41.3 % 0.552
Relationship status:
currently married/defacto 79.6 % 68.1 % 0.066
Country of birth:
Australia 83.7 % 85.1 % 0.506
United Kingdom 9.0 % 8.5 % 0.584
Highest level of education completeda:
< yr 12 24.7 % 25.0 % 0.565
certificate, Trade etc. 31.7 % 39.4 % 0.245
yr 12 10.4 % 3.0 % 0.149
university 35.7 % 33.3 % 0.476
Labour force participation:
employed full time 32.1 % 17.0 % 0.026
employed part-time 15.4 % 14.9 % 0.568
self-employed 9.0 % 10.6 % 0.455
retired 25.3 % 19.1 % 0.242
Unemployed 5.4 % 4.3 % 0.542
aFor this question, n = 33 for the non-completer group
Table 3 Comparison of HH cohort and Australian population normative utility values [23]
Variables Mean
HSUV
95 % CI n Males Females Population
norm
HSUV
95 % CI
Mean HSUV 95 % CI n Mean HSUV 95 % CI n
Age group:
20–29 0.67 0.55–0.80 10 0.75 0.53–1.00 2 0.65 0.49–0.70 8 0.86 0.85–0.87
30–39 0.72 0.62–0.80 30 0.78 0.66–0.90 7 0.70 0.59–0.81 23 0.84 0.83–0.85
40–49 0.66 0.57–0.74 39 0.72 0.57–0.84 15 0.62 0.50–0.74 24 0.81 0.80–0.82
50–59 0.63 0.54–0.70 52 0.62 0.47–0.75 19 0.63 0.54–0.71 33 0.80 0.78–0.81
60–69 0.67 0.61–0.73 67 0.70 0.62–0.78 34 0.65 0.54–0.74 33 0.80 0.78–0.81
70–79 0.61 0.47–0.73 16 0.63 0.47–0.76 11 0.56 0.21–0.92 5 0.76 0.76–0.79
Sex
Male 0.69 0.64–0.75 92 0.82 0.81–0.83
Female 0.64 0.60–0.69 129 0.81 0.80–0.81
All 0.66 0.63–0.70 221 0.81 0.81–0.82
Note: HSUV refers to health state utility values; 95 % CI refers to the 95 % confidence interval
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failure, cardiomyopathy, diabetes and porphyria cutanea
tarda, only small numbers of participants reported these
co-morbidities, therefore these should be interpreted with
caution (Table 6).
Participants were also asked to report on experience of
symptoms related to HH and iron overload in the preced-
ing three months (Table 7). Participants were asked if they
thought these symptoms were related to HH, possibly
related or not related. Only participants reporting their
symptoms to be related to HH were included to minimise
over-reporting. Of a maximum of 20 symptoms and con-
ditions, the median number experienced by the sample
was 3 (SD = 3.8, range 0–15). When compared with the
reference HSUV, all symptoms were associated with lower
utility. A Pearson correlation coefficient was calculated to
assess the relationship between symptom count and
HSUV, and a strong negative correlation was found
(r = −0.685; p < 0.001) (Fig. 1).
Discussion
This is the first study that reports HSUV measured dir-
ectly from a cohort with HH. This is of importance, as a
lack of robust health economic data has been cited as a
barrier to implementing population screening programs
for HH [25, 30, 31, 42]. The utility values calculated in this
study provide robust estimates that can be used in future
economic models of screening interventions. Whilst the
sampling strategy may have introduced bias, this has been
mitigated by reporting utility values for categories of HH
rather than across the study population in general. These
values can then be used in combination with penetrance
rates in economic models for HH interventions.
Symptomatic stages of HH (categories three and four
[25]) were associated with lower utility than asymptom-
atic stages. The values for all four categories are useful,
as they incorporate all aspects of HH and related condi-
tions and can be used to populate health economic
models. Previous CUA models have only incorporated
specific comorbidities which are associated with signifi-
cant morbidity and mortality: cirrhosis, diabetes and
heart failure, with no consideration of common comor-
bidities such as arthritis, or symptoms such as fatigue.
This may be related to the relatively high prevalence of
both fatigue and arthritis amongst other populations,
Table 4 Mean utility values by categories of HH by sex
Categories of HH HSUV mean SD n 95 % CI
All participants
Category 1 0.76 0.21 20 0.67–0.85
Category 2 0.81 0.18 63 0.76–0.85
Category 3 0.60 0.27 115 0.55–0.66
Category 4 0.50 0.27 23 0.39–0.61
All categories 0.66 0.26 221 0.63–0.70
Males
Category 1 0.88 0.10 6 0.78–0.98
Category 2 0.85 0.12 29 0.80–0.89
Category 3 0.59 0.28 45 0.51–0.68
Category 4 0.59 0.23 12 0.44–0.74
All categories 0.69 0.27 92 0.64–0.75
Females
Category 1 0.71 0.24 14 0.58–0.84
Category 2 0.77 0.21 34 0.70–0.85
Category 3 0.60 0.26 70 0.54–0.66
Category 4 0.41 0.29 11 0.22–0.60
All categories 0.64 0.26 129 0.60–0.69
Note: HSUV refers to health state utility values; SD standard deviation; 95 % CI
refers to the 95 % confidence interval
Table 5 Mean utility values of symptomatic HH
Categories of HH HSUV mean SD n 95 % CI Between groupsa
All participants
Categories 1 & 2 0.80 0.19 83 0.76–0.84 H = 38.79, p < 0.001
Categories 3 & 4 0.58 0.27 138 0.54–0.63
All categories 0.66 0.26 221 0.63–0.70
Males
Categories 1 & 2 0.85 0.11 35 0.82–0.89 H = 25.36, p < 0.001
Categories 3 & 4 0.59 0.27 57 0.52–0.67
All categories 0.69 0.26 92 0.64–0.75
Females
Categories 1 &2 0.75 0.22 48 0.69–0.82 H = 14.90, p < 0.001
Categories 3 & 4 0.58 0.27 81 0.52–0.64
All categories 0.64 0.64 129 0.60–0.69
Note: HSUV refers to health state utility values; SD standard deviation; 95 % CI refers to the 95 % confidence interval
aKruskal Wallis one way analysis of variance was used for this test for significance
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and the difficulties surrounding the aetiologies of both,
however there is evidence suggesting that the prevalence
of both is higher amongst some groups of HH patients.
The prevalence of fatigue amongst general practice pa-
tients has been estimated to be between 1.4 and 7.0 % of
encounters [43–46]. Work by Allen and colleagues has
reported a much higher rate of 22 % for C282Y homozy-
gotes with elevated serum ferritin levels (greater than
1,000 μg/l) [10]. Similarly, arthritis, specifically osteo-
arthritis, is prevalent in Australia, with 9 % reporting
this condition [47]. Allen and colleagues reported use of
arthritis medication as a proxy measure for arthritis,
noting that 20 % of C282Y homozygotes with serum fer-
ritin greater than 1,000 μg/l reported use of these medi-
cations. In combination, these data guided the decision
to include arthritis and fatigue in the current study.
To date, just four cost utility analyses have been pub-
lished on HH screening programs, none of which cited
the sources of the utility values employed [7, 48–50].
Values were assigned for cirrhosis, diabetes and heart
failure, and in some cases, combinations of these. In a
Norwegian study [48], a basal utility value of 1.00 was
assumed for all HH conditions except cirrhosis, which
was assigned a utility of 0.95, values that are
substantially higher than those reported here. Two Can-
adian studies, by the same research group, used utilities
of 0.8 for cirrhosis, 0.9 for diabetes, 0.5 for heart failure,
0.72 for cirrhosis and diabetes, 0.78 for cirrhosis and
heart failure, 0.87 for diabetes and heart failure and 0.70
for a combination of cirrhosis, diabetes and heart failure
[7, 49]. A fourth study did not provide the utility values
used in the modelling [50]. Some concerns arise in re-
spect of these estimates. First, in comparing these utility
values to US population normative data, a disparity ap-
pears: the mean utility derived from the SF-6D ranged
from 0.79 to 0.81 for persons aged 35 to 74, and simi-
larly, using the EQ-5D, mean utility ranged between 0.87
and 0.89 [51]. The fact that the utility estimates that
were used in cost utility analyses for participants with
health conditions such as cirrhosis and diabetes are simi-
lar to or higher than those reported for the general US
population indicates these estimates may be incorrect.
The likely overestimates of HSUV for HH-related condi-
tions are likely to lead to underestimates of potential
utility gains associated with screening interventions.
Second, disease specific HSUV used in these cost util-
ity analyses are also higher than suggested in published
literature. A meta-analysis of utility values for liver
diseases using a range of approaches to measure utility
reported a mean of 0.75 for compensated cirrhosis
(range 0.65–0.90) and 0.67 for decompensated cirrhosis
(range 0.57–0.81) [52]. Whilst our study did not differ-
entiate cirrhosis in this manner, amongst the small num-
ber of participants reporting this condition (n = 5), the
mean utility (0.61) was slightly lower than reported for
decompensated cirrhosis but within the range reported.
In contrast, the published cost utility analyses used
values of 0.95 [48] and 0.8 [7, 49], higher than the mean
values reported for both compensated and decompen-
sated cirrhosis [52]. Similarly, a meta-analysis of utility
values for diabetes reported a mean of 0.76 (range 0.53–
0.88) [53]. In our study, a mean of 0.52 was reported (n
= 4), slightly lower than the lower range reported in this
meta-analysis. In the three HH cost utility analyses, one
used a utility value for diabetes of 1.00 [48], and two
used a value of 0.9 [7, 49], both notably higher than pub-
lished estimates.
Mean utility for heart failure varies depending on the
severity of the condition. From a large, multi-site trial
that used the EQ-5D, mean utility for different levels of
severity based on the New York Heart Association
(NYHA) classifications were: class I: 0.815, class II:
0.720, class III: 0.590, class IV: 0.508 [54]. Our study re-
ported a mean of 0.58, however data were available for
only three participants, and all were in different NYHA
classes. The two Canadian CUA models used a utility
value of 0.5 [7, 49], which is similar to the NYHA
class 4. In contrast, the Norwegian study assumed a
Table 6 Mean utility values by self-reported HH-related
comorbidities
HH-related comorbiditiesa mean HSUV SD n
All participants
no comorbidity 0.76 0.21 100
arthritis 0.52 0.25 35
fibrosis 0.53 0.29 7
cirrhosis 0.61 0.31 5
heart failure 0.58 0.24 3
cardiomyopathy 0.30 - 1
diabetes 0.52 0.33 4
porphyria cutanea tarda 0.02 - 1
Males
no comorbidity 0.76 0.25 39
arthritis 0.59 0.23 15
fibrosis 0.69 0.05 5
cirrhosis 0.74 0.16 3
Females
no comorbidity 0.76 0.19 61
arthritis 0.48 0.26 20
fibrosis 0.12 0.02 2
cirrhosis 0.42 0.45 2
Note: HSUV refers to health state utility values; SD standard deviation
aParticipants were asked if they had been diagnosed with these conditions
and that they were considered to be related to HH and iron overload.
Participants with these conditions, but were unsure if they were related to HH
were not included in this analysis
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utility of 1.00, which is not in keeping with estimates
in the current literature [48].
To date, no economic analysis has incorporated HSUV
related to arthritis. This is surprising as arthritis related to
iron overload is commonly reported amongst patients diag-
nosed with HH [10, 55–57]. Whilst HRQoL is not syn-
onymous with HSUV, it can serve as an indicator. A study
examining the effects of a range of HH-related comorbidi-
ties using the SF-36 found that, compared to cirrhosis and
diabetes, arthritis was the single strongest factor that im-
pacted on HRQoL [58]. Whilst the paper was published in
1996, no subsequent studies have incorporated utility
values for arthritis. Hawthorne and colleagues, using the
AQOL-4D, reported the Australian normative utility value
for arthritis as 0.69 (SD 0.26). Our study reported a lower
mean value of 0.52 (SD 0.25, n = 35). In the current study,
both self-reported diagnosis of arthritis related to HH and
symptoms suggestive of arthritis were associated with lower
Table 7 Mean utility values for HH related symptoms
Experienced in the last 3 months mean
HSUV
SD n Males Females
mean HSUV SD n mean HSUV SD n
General effects
Chronic fatigue 0.55 0.29 102 0.56 0.31 37 0.55 0.29 65
Weakness 0.49 0.26 87 0.51 0.28 33 0.48 0.26 54
Unexplained weight loss 0.42 0.40 10 1.00 - 1 0.35 0.36 9
Unexplained weight gain 0.50 0.26 30 0.37 0.31 8 0.55 0.23 22
Liver disease
Abdominal swelling 0.40 0.25 35 0.41 0.33 9 0.39 0.22 26
Abdominal pain/discomfort 0.47 0.26 47 0.51 0.31 12 0.46 0.25 35
Enlarged liver (hepatomegaly) 0.40 0.24 15 0.57 0.19 6 0.29 0.21 9
Cardiac-related problems
Swelling of feet and/or ankles 0.46 0.23 47 0.43 0.24 17 0.48 0.22 30
Shortness of breath- walking quickly or uphill 0.50 0.27 64 0.54 0.27 24 0.48 0.26 40
Shortness of breath- walking on level ground 0.36 0.26 29 0.39 0.26 14 0.33 0.27 15
Shortness of breath- resting in a chair 0.31 0.25 8 0.32 0.45 3 0.21 0.24 5
Heart failure or weak heart 0.30 - 1 0.30 - 1 - - -
Abnormal heart rhythm/ arrhythmia 0.55 0.23 25 0.61 0.17 8 0.52 0.26 17
Heart disease 0.52 0.27 6 0.49 0.28 5 0.71 - 1
Arthritis
Swollen/tender metacarpophalangeal joints (fingers/hands) 0.48 0.25 58 0.47 0.30 21 0.49 0.22 37
Other joint stiffness/pain/ache 0.55 0.26 96 0.6 0.26 39 0.51 0.24 57
Skin changes
Change in skin colour 0.45 0.29 25 0.50 0.35 8 0.43 0.27 17
Increased facial hair growth 0.32 0.21 14 - - - 0.32 0.21 14
Reproductive
Loss of libido and/or erectile dysfunction 0.49 0.27 49 0.48 0.27 17 0.49 0.28 32
Unexplained confusion and/or memory loss 0.40 0.24 53 0.39 0.25 18 0.41 0.24 35
Note: HSUV refers to health state utility values; SD standard deviation
Fig. 1 Linear regression of HSUV and symptom count related to HH
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mean utility than the sample mean (0.52, 0.48, 0.66
respectively).
Limitations of this study include cross-sectional design
and use of convenience sampling. Convenience sampling,
which was used as a result of available resourcing, may
limit the generalizability of these results. Further, the
majority of the respondents were female, despite higher
penetrance amongst males. To minimise sampling bias,
we have focused on utility values for categories of disease
and symptomatology for males and females separately.
Whilst an overall sample mean HSUV is likely to be
affected by under- or over-reporting from participants
with more health problems, the mean values for each
category are not affected. This allows for these values, in
combination with penetrance estimates from robust epi-
demiological studies, to be used in HH health economic
models.
A further limitation of this study was the reliance on
participants’ self-report regarding experience of HH re-
lated comorbidities and symptoms. Whilst participants
were asked if the comorbidities were related to HH, even
with clinical verification, it is difficult to be certain of the
aetiology of these. Whilst it can be argued that there may
be some over-reporting of symptoms and comorbidities
believed to be caused by HH, to minimise this possibility,
cases in which participants were unsure of the aetiology
have been excluded. Symptoms and comorbidities were
only included when participants stated that they were
related to HH. Lastly, the small number of participants
reporting HH-related comorbidities was also a limitation.
Whilst utility values were calculated wherever possible,
the small number of respondents means that these data
should be interpreted with caution and that no meaningful
comparisons can be made between these comorbidities.
Conclusions
In conclusion, this is the first study to report utility
values measured directly from people with HH. Despite
study limitations, these values are the best available to
date, and can be used to populate health economic
models investigating the cost utility of HH interventions.
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